SCHEMBL30775294

SCHEMBL30775294

Fc1cnc(NCC2CC2)nc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.48
MERTK Q12866 2/20 0.40
FLT3 P36888 1/20 0.40
TYRO3 Q06418 1/20 0.40
GAS6 Q14393 1/20 0.40
ABL1 P00519 1/20 0.40
GRIN2B Q13224 2/20 0.39
PRKCQ Q04759 4/20 0.39
HRH4 Q9H3N8 1/20 0.39
VNN1 O95497 1/20 0.39
ACACB O00763 1/20 0.39
VCP P55072 3/20 0.38
IDH1 O75874 1/20 0.38
IDH2 P48735 1/20 0.38
PRKD3 O94806 1/20 0.38
MAP4K4 O95819 1/20 0.38
PRKCG P05129 1/20 0.38
FGFR1 P11362 1/20 0.38
MAPK1 P28482 1/20 0.38
FLT4 P35916 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5359238 0.88 IGF1R (0.44) KCNH2MERTKFLT3TYRO3GAS6
SCHEMBL9967142 0.80 NPC1 (0.41) KCNH2GRIN2BPRKCQHRH4VNN1
SCHEMBL10293572 0.80 MAPK1 (0.44) KCNH2GRIN2BPRKCQHRH4VNN1
SCHEMBL20386427 0.80 HRH4 (0.39) KCNH2GRIN2BHRH4VNN1ACACB
SCHEMBL13685177 0.80 PTGER4 (0.40) KCNH2GRIN2BPRKCQHRH4VNN1
SCHEMBL14670813 0.77 GRIN2B (0.43) KCNH2GRIN2BHRH4VNN1ACACB
SCHEMBL24104433 0.76 ACACB (0.44) KCNH2GRIN2BPRKCQHRH4VNN1
SCHEMBL19418484 0.76 CRHR1 (0.54) KCNH2MERTKFLT3TYRO3GAS6
SCHEMBL21916863 0.76 VNN1 (0.39) KCNH2GRIN2BHRH4VNN1ACACB
SCHEMBL14667083 0.76 GRIN2B (0.43) KCNH2GRIN2BPRKCQHRH4VNN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US claimed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR KCNH2 4247/4885MERTK 4786/4885FLT3 4791/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR KCNH2 4247/4885MERTK 4786/4885FLT3 4791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.